grant
Mapping and targeting 3D regulatory elements in leukemia and lymphoma-Supplement
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 13 Dec 2024Deadline 30 Nov 2029
NIHUS FederalResearch GrantFY20253-D3-D analysis3-D structure3-Dimensional3-dimensional analysis3-dimensional structure3D3D analysis3D structureAML - Acute Myeloid LeukemiaAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAcute T Cell LeukemiaAcute T-Cell Lymphoblastic LeukemiaAcute T-Cell Lymphocytic LeukemiaAcute T-Lymphocytic LeukemiaAcute leukemiaAdministrative SupplementAffectAfrican AmericanAfrican ancestryAfrican descentAfro AmericanAfroamericanAmericanArchitectureAutoregulationAwardB23BiologicalBlackBlack AmericanBlack raceBlood SampleBlood specimenBone MarrowBone Marrow Reticuloendothelial SystemCancer ControlCancer Control ScienceCancersCell BodyCellsChromatinChromosomal OrganizationChromosomal StructureChromosome OrganizationChromosome StructuresClinical TrialsDNADNA mutationDataDedicationsDeoxyribonucleic AcidDiseaseDisease OutcomeDisorderDisparitiesDisparityDrug TherapyDysplasiaElementsEngineering / ArchitectureEnhancersEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEssential GenesEuropeanEuropean ancestryExpression SignatureFrequenciesFunctional RNAGene ExpressionGene Expression ProfileGene TranscriptionGeneralized GrowthGenesGeneticGenetic ChangeGenetic DiseasesGenetic RiskGenetic TranscriptionGenetic defectGenetic mutationGrowthHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHeterogeneityHomeostasisHumanImmune systemIndividualInferiorInflammationIntratumoral heterogeneityLeukemic progenitor and stem cellMalignantMalignant - descriptorMalignant Hematopoietic NeoplasmMalignant NeoplasmsMalignant TumorMapsModern ManModificationMultiple MyelomaMutationNPMNPM1NPM1 geneNoncoding RNANontranslated RNANuclearOutcomePatientsPharmacological TreatmentPharmacotherapyPhysiological HomeostasisPlasma-Cell MyelomaPlayPrecursor T Lymphoblastic LeukemiaRNA ExpressionRNA SeqRNA sequencingRNAseqReactionRegulatory ElementRiskRisk MarkerRoleSamplingShapesStem Cell likeStressStudy modelsT-Cell LeukemiaT-Cell Lymphocytic LeukemiaT-Cell LymphomaT-Cell Non-Hodgkin's LymphomaT-Cell NonHodgkins LymphomaT-Cell Type Acute LeukemiaT-Cell and NK-Cell Non-Hodgkin's LymphomaT-CellsT-LymphocyteT-Lymphocytic LeukemiaT-lineage acute lymphoblastic leukemiaTestingTextThree-dimensional analysisTissue GrowthTranscriptionTranscriptional ControlTranscriptional RegulationTumor CellUntranslated RNAacute granulocytic leukemiaacute myeloid leukemiabiologicblack patientblood cancercancer disparitycancer health disparitycancer of bloodcancer of the bloodcancer progressioncancer-related health disparitycaucasian Americandesigndesigningdisease riskdisease subgroupsdisease subtypedisorder riskdisorder subtypedisparity in cancerdriver lesiondriver mutationdrug interventiondrug treatmentdyscrasiaentire genomeepigenetic regulationepigeneticallyexomeexperimentexperimental researchexperimental studyexperimentsfull genomegene expression patterngene expression signaturegenetic conditiongenetic disordergenome mutationgenome sequencingglobal gene expressionglobal transcription profileheterogeneity in tumorshigh riskimprovedin silicoinnovateinnovationinnovativeintra-tumoral heterogeneityintratumor heterogeneityleukemialeukemia stem/initiating cellsleukemia/lymphomaleukemic progenitorleukemic stem celllong read seqlong-read sequencinglong-read transcript sequencinglymphoma/leukemiamalignancymyelomamyelomatosisneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnon-geneticnoncodingnongeneticnovelontogenyoutcome predictionparticipant enrollmentpatient enrollmentpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsprogenitorprogenitor capacityprogenitor cell likeprogenitor-likeprogramspromoterpromotorresponseresponse to therapyresponse to treatmentrisk predictorrisk predictorsrisk stratificationscATAC sequencingscATAC-seqself-renewself-renewalsingle cell ATAC-seqsingle cell ATAC-sequencingsingle cell Assay for Transposase Accessible Chromatin sequencingsingle cell sequencing assay for transposase accessible chromatinsingle moleculesingle-cell Assay for Transposase-Accessible Chromatin with sequencingsingle-cell assay for transposase-accessible chromatin using sequencingsingle-cell assay for transposase-accessible chromatin-seqsocial rolesocio-economicsocio-economicallysocioeconomicallysocioeconomicsstem cell characteristicsstem-likestemnessstratify riskstressortherapeutic responsetherapy responsethree dimensionalthree dimensional structurethymus derived lymphocytetranscriptional profiletranscriptional signaturetranscriptometranscriptome sequencingtranscriptomic sequencingtreatment responsetreatment responsivenesstumor heterogeneitytumor progressiontumorigenicwhite Americanwhole genome
Description preview
Project Summary/Abstract (underlined are the added text and data related to this administrative supplement)
Despite cancer being typically depicted as a genetic disease, aberrations in epigenetic regulation and gene
expression play a determinant role in transformation and response to therapies. Increased chromatin plasticity
gives a survival…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click